Teasing out relevant markers and learning more about what patients tumours are telling us is key
What's looking interesting in early stage trials at ASCO24?
Next generation agents or a new drug class?
Our 7th AACR Preview takes stock of an emerging class of anti-cancer agents
There is beauty in drugging intractable targets
What to watch out for in DDR, epigenetic therapies, and other hot topics
Parsing cancer research hype at ESMO23
A look at some hot topics from the TARGETS/TRIPLE meeting in Boston
Off the beaten track can bring danger and delight in the unknown in equal measure
It’s all too easy to think of New Jersey as the behemoth of Pharmaland in the north east, while…
How the landscape in prostate cancer could change in the medium to long term
Can we overcome resistance checkpoint blockade with novel approaches to DDR?
Are all PARP inhibitors the same?
An emerging new and highly selective oncogenic target
Can NK cells help checkpoint blockade work more effectively?
Finding new synthetic lethal targets to induce more potent cell death and improve outcomes
Is the OlympiA trial groundbreaking for early stage breast cancer?
Surprises galore in the unveiling of the PARP data in 1L mCRPC!
Cracking the tumour code
Exploring new approaches to targeting cancer
SITC 2021 Preview
A detailed look at Repare's ATR inhibitor data from the TRIPLE meeting
Can a genomic signature help select patients more accurately for DDR therapies?
PARP plus IO and IO combos are becoming all the rage, what can we learn from early signals?
How can AI and ML speed up or improve our drug discovery efforts in oncology R&D?
Olaparib is the first PARP to demonstrate a clinical benefit in HER2- breast cancer - what do KOLs really think?
Latest preclinical and clinical news and readouts as well as forthcoming trial presentations to look forward to in the DDR space
New product development and early phase anti-cancer agents have been very much a focus on BSB (and PSB…
PARP inhibitors move into the adjuvant setting at long last? Say it ain't so!
A look at some hidden gems in the ASCO program and what it all means in terms of the science.
New research is emerging which may have an impact on future trial designs as well as combination partners and even different tumour types.
Some key learnings from the ESMO Breast Cancer meeting held last week
Bridging the DDR gap from AACR to ASCO
What's hot on the DDR front and PARP inhibitor space at AACR21?
Emerging areas in cool new science around targeted therapies
Post SABCS analysis of a key topic and cancer driver
new approaches to applying translational research to the clinic in oncology R&D
The trials and tribulations of targeted agents in developmental therapeutics
Winners, losers and risers... who goes where in the final analysis?
A look at one oncology biotech company's early pipeline and how it fits in with the emerging landscape
Surprising new developments in early stage breast and metastatic prostate cancers
What to watch out for this weekend in targeted therapies and early stage new product development
New developments in the DDR niche suggest a whole new approach to tackling solid tumours beyond women's cancers, pancreatic and prostate cancer might be feasible.
A look at five novel anti-cancer agents in early R&D pipelines and what we can learn from their experiences
Ten intriguing novel agents in early development to watch out for
What can we learn from the phase 2 trials with PARP inhibitors in mCRPC? Quite a lot, it would seem...
Insights from a US KOL on the phase 3 PROfound trial exploring olaparib in mCRPC
Highlights from the PROfound trial in advanced prostate cancer and other stories of interest
Key findings and commentary on the third day of ESMO
Insights from Day 2 of ASCO19, plus a look at what to expect in the plenary and other sessions today.
We've heard much about PARP inhibitors but they aren't the only targets in DDR we can hit...
Are the PARPi a class effect or are there real differences between them that may become more apparent in future combo studies?
How can we improve on monotherapy with PARP inhibitors? How do we address primary and acquired resistance?
A look at PARP as it journeys from 1999 to 2017 culminating in a plenary presentation at ASCO
A look a one company's approach to DDR and potential combination opportunities in this niche
A candid look at new approaches being explored in cold tumours using prostate cancer as an example
A look at what we can learn from some recently published new papers in the oncology space.
Exploring clinical trials with targeted therapies, including PARP and ATR inhibitors and combination approaches
How does the rucaparib data at ESMO fit in the treatment paradigm and what's next for PARPi?
Following the dispute between Tesaro and Myriad on HRD testing, here's Myriad's perspective on the data presented
What you need to know about the Tesaro niraparib ovarian cancer data presented at ESMO 2016.
Biomarin have a good shot on goal with their PARP inhibitor talazoparib in gBRCA breast cancer
With the intense focus on immino-oncology, are targeted agents passe now?
The first readout from the I-SPY2 neoadjuvant breast cancer trial comes from the veliparib (PARP) arm.
